Friday, September 25

Browsing: Sevabertinib

Diagnosis

How Sevabertinib Stacks Up Against Other HER2-Directed NSCLC Options

By NewsCancerSeptember 24, 20260

Sevabertinib (Hyrnuo) is an oral HER2 tyrosine kinase inhibitor (TKI) with FDA accelerated approval for frontline use in HER2-mutant non–small…

Treatments

By NewsCancerSeptember 9, 20260

The FDA has granted accelerated approval to sevabertinib (Hyrnuo) as a treatment for those with locally advanced or metastatic nonsquamous…

Diagnosis

By NewsCancerAugust 25, 20260

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved sevabertinib (Hyrnuo) for the treatment of patients with…

Survivors

By NewsCancerMay 18, 20260

The FDA has granted priority review to a supplemental new drug application (sNDA) for frontline sevabertinib (Hyrnuo) among adults with…